Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
Chronic Kidney Disease is a growing epidemic with 850 million people affected worldwide.
More than 5 lakh patients availed the benefit of queue-less OPD registration using this service
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
